Navigation Links
Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
Date:10/14/2008

A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted. The study is published in the October 18, 2008 issue of the journal AIDS.

"Our findings add to existing limited evidence that efavirenz-based therapies produce a more favorable virological and clinical outcome than nevirapine," says Jean Nachega, MD, PhD, MPH, lead author of the study and associate scientist with the Bloomberg School's Department of International Health. "Patients started on nevirapine had an increased risk of virologic failure and death, were significantly less likely than those started on efavirenz to achieve high treatment adherence."

Nachega, in collaboration with Gary Maartens, MD, FCP, professor of Medicine at University of Cape Town, and several other colleagues from the University of Cape Town in South Africa, examined the records of 2,817 HIV- infected adults currently enrolled in Aid for AIDS, a private-sector employer-subsidized disease management program in Africa. Participants were HAART nave adults who began nevirapine-based or efvirenz-based therapies between January 1998 and September 2004. Researchers determined how often patients requested reimbursement for their purchases of nevirapine- or efavirenz-based HAART to estimate adherence to their treatment regimens. They also evaluated patients CD4 counts, viral load changes and mortality, which are measurements that indicate how well a treatment is working. Program participants were in nine countries in Africa with the majority in South Africa.

Current World
'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Catcher Holdings Inc. Lands Contract for Initial Deployments at Nine Homeland Security and State Government Agencies
2. Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing
3. Landmark study unlocks stem cell, DNA secrets to speed therapies
4. Argyrin: Natural substance raises hope for new cancer therapies
5. Newly identified role for power plants in human cells could lead to targeted therapies
6. 2 new therapies show promise for cancer patients
7. Challenges and promise of cell-based therapies
8. The construction of heart modelling leads path to new therapies
9. NCI renewal grant to develop new cancer therapies
10. Linchpin gene may be useful target for new breast cancer therapies
11. Low sperm count may be associated with prenatal testosterone excess
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... Independence from fossil fuel exporting nations, a reduction ... there are any number of reasons to stop the use ... probably provide the solution to our global energy problemin the ... to bioenergy. Biomass can be used to generate alternative carbon-based ...
... the Summer Olympics in Beijing kicks off today, ... of Oceanography, UC San Diego, a once-in-a-lifetime opportunity ... heavily populated region substantially curbs everyday industrial emissions. ... Experiment (CAPMEX) will include a series of flights ...
... making the grade with the,introduction of the stylish Cyber-shot(R) ... The 10-megapixel T77 camera is Sony,s thinnest model at ... x 9 touch panel LCD screen. It features,updated intelligent ... child and adult priority, as well as high,sensitivity shooting ...
Cached Biology News:Fuel from cellulose 2Scripps scientists will assess Beijing Olympics air pollution control efforts 2Scripps scientists will assess Beijing Olympics air pollution control efforts 3Sony Cyber-shot Cameras Get Smarter 2Sony Cyber-shot Cameras Get Smarter 3
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
(Date:5/29/2015)... The Academy of Model Aeronautics has awarded ... from across the nation. , The Academy of Model ... Youth Members with scholarships to pursue technical careers. Since ... awarded nearly $900,000 to college-bound aero-modelers. The scholarships are ... individuals, AMA member donations, a portion of AMA member ...
(Date:5/29/2015)... LONDON , May 29, 2015 ... forward as p ersonalized   treatments enter ... Despite generic erosion facing several of ... xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), the global ... growth by the end of the decade.   ...
(Date:5/29/2015)... 29, 2015 Market Publishers Ltd ... signed a partnership agreement for quality market research ... distribute and sell research reports worked out by ... Department, commented upon the agreement: “Chem-Report is a ... petroleum and chemical markets on global and country ...
Breaking Biology Technology:Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Academy of Model Aeronautics Awards $46,500 in Scholarships to College-Bound Model Aviation Pilots 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3
... ISLAND, S.C., Aug. 6 Denham Capital,("Denham") ... to $60 million in VitAG,Corporation ("VitAG"). VitAG ... fertilizer product capable of competing with and,outperforming ... of multiple biosolids-to-fertilizer manufacturing plants., "Denham,s ...
... Update Call on Tuesday, August 12, 2008, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics for ... financial results for the three and six-month periods ... ), The Company reported a net loss ...
... is voluntarily recalling one manufacturing lot (P114942A) of,PROCRIT(R) (Epoetin alfa) after ... upon post-manufacturing inspection. No other lot of,this product is affected by ... configurations were distributed between,April 15, 2008 and July 17, 2008., , ... Description ...
Cached Biology Technology:Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2EntreMed Reports Second Quarter 2008 Financial Results 2EntreMed Reports Second Quarter 2008 Financial Results 3EntreMed Reports Second Quarter 2008 Financial Results 4EntreMed Reports Second Quarter 2008 Financial Results 5Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A 2
... The kit for stabilizing 50g of purified ... StabMRT Plus Kit delivers all of the advantages ... but in addition the RNA can be used ... , This product has been optimised for the ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Plasmid expressing Zeocin resistance gene....
...
Biology Products: